全文获取类型
收费全文 | 3053篇 |
免费 | 166篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 124篇 |
妇产科学 | 31篇 |
基础医学 | 476篇 |
口腔科学 | 93篇 |
临床医学 | 202篇 |
内科学 | 747篇 |
皮肤病学 | 91篇 |
神经病学 | 267篇 |
特种医学 | 124篇 |
外科学 | 278篇 |
综合类 | 17篇 |
预防医学 | 152篇 |
眼科学 | 91篇 |
药学 | 232篇 |
中国医学 | 9篇 |
肿瘤学 | 293篇 |
出版年
2023年 | 25篇 |
2022年 | 33篇 |
2021年 | 70篇 |
2020年 | 41篇 |
2019年 | 60篇 |
2018年 | 72篇 |
2017年 | 59篇 |
2016年 | 57篇 |
2015年 | 70篇 |
2014年 | 100篇 |
2013年 | 129篇 |
2012年 | 190篇 |
2011年 | 223篇 |
2010年 | 129篇 |
2009年 | 117篇 |
2008年 | 196篇 |
2007年 | 233篇 |
2006年 | 205篇 |
2005年 | 195篇 |
2004年 | 217篇 |
2003年 | 205篇 |
2002年 | 232篇 |
2001年 | 21篇 |
2000年 | 15篇 |
1999年 | 29篇 |
1998年 | 30篇 |
1997年 | 27篇 |
1996年 | 24篇 |
1995年 | 22篇 |
1994年 | 21篇 |
1993年 | 26篇 |
1992年 | 17篇 |
1991年 | 11篇 |
1990年 | 11篇 |
1989年 | 12篇 |
1988年 | 9篇 |
1987年 | 4篇 |
1986年 | 5篇 |
1985年 | 8篇 |
1984年 | 8篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1978年 | 10篇 |
1977年 | 9篇 |
1973年 | 5篇 |
1971年 | 4篇 |
1969年 | 4篇 |
排序方式: 共有3234条查询结果,搜索用时 15 毫秒
81.
Aim: We report two patients with Panayiotopoulos syndrome (PS) who developed encephalopathy related to status epilepticus during slow sleep (ESES) at the peak of their clinical course. Methods: Clinical charts and EEG data were reviewed. Results: The patients exhibited nocturnal autonomic seizures and occipital EEG foci, the latter of which later evolved into multifocal EEG foci with synchronous frontopolar and occipital spikes (Fp‐O EEG foci), and finally into continuous spikes‐waves during sleep (CSWS; spike‐wave index >85% based on whole‐night sleep recording) at eight years and seven years of age, respectively. The occipital spikes always preceded frontopolar spikes by 30~50 mseconds based on the analysis of CSWS. Neuropsychological ability, including IQ, deteriorated during the CSWS period in both patients. The autonomic seizures and focal to bilateral tonic‐clonic seizures were initially resistant to antiepileptic drugs (AEDs), and occurred more than 10 times in both patients. However, the seizures and EEG findings gradually resolved, and AEDs were successfully terminated in both patients. Conclusion: PS can progress to ESES if the clinical course exhibits atypical evolution. The initial autonomic symptom of the seizures and interictal Fp‐O EEG foci should be carefully monitored in patients with CSWS or ESES. 相似文献
82.
83.
Takehiko Mori Souichi Shiratori Junji Suzumiya Mineo Kurokawa Motohiro Shindo Uchida Naoyuki Takenaka Katsuto Toshihiro Miyamoto Satoshi Morishige Makoto Hirokawa Takahiro Fukuda Yoshiko Atsuta Ritsuro Suzuki 《Hematological oncology》2020,38(3):266-271
Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome. 相似文献
84.
85.
86.
Debra Lynch Kelly David Buchbinder Rafael F. Duarte Jeffrey J. Auletta Neel Bhatt Michael Byrne Zachariah DeFilipp Melissa Gabriel Anuj Mahindra Maxim Norkin Helene Schoemans Ami J. Shah Ibrahim Ahmed Yoshiko Atsuta Grzegorz W. Basak Sara Beattie Sita Bhella Christopher Bredeson Bronwen E. Shaw 《Biology of blood and marrow transplantation》2018,24(2):228-241
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT. 相似文献
87.
Yoshiko Tomita Emma Hansson Florent Mazuir Gustaf J Wellhagen Qing Xi Ooi Enrica Mezzalana Atsushi Kitamura Daisuke Nemoto Sbastien Bolze 《CTS Clinical and Translational Science》2022,15(4):1014
Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal dosing regimen for Japanese patients with T2DM and chronic kidney disease (CKD). Imeglimin plasma concentrations in Japanese and Western healthy volunteers, and patients with T2DM, including patients with mild to severe CKD with an estimated glomerular filtration rate (eGFR) greater than 14 ml/min/1.73 m2 were included in a population PK analysis. PK simulations were conducted using a population PK model, and the area under concentration‐time curve (AUC) was extrapolated with power regression analysis to lower eGFR. The influence of eGFR, weight, and age on apparent clearance and of dose on relative bioavailability were quantified by population PK analysis. Simulations and extrapolation revealed that the recommended dosing regimen based on the AUC was 500 mg twice daily (b.i.d.) for patients with eGFR 15–45 ml/min/1.73 m2, and 500 mg with a longer dosing interval was suggested for those with eGFR less than 15. Simulations revealed that differences in plasma AUCs between Japanese and Western patients at the same dose were mainly driven by a difference in the eGFR and that the plasma AUC after 1000 and 1500 mg b.i.d. in Japanese and Western patients, respectively, was comparable in the phase IIb studies. These results indicate suitable dosages of imeglimin in the clinical setting of T2DM with renal impairment. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THIS STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
88.
Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone 总被引:4,自引:0,他引:4
Kitamura A Mizuno Y Natsui K Yabuki M Komuro S Kanamaru H 《Biopharmaceutics & drug disposition》2005,26(2):59-65
In vitro studies were carried out to identify the major contribution of CYP2C8, CYP2D6 and CYP3A4 to the metabolism of perospirone (cis-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]cyclohexane-1,2-dicarboximide monohydrochloride dehydrate), a novel antipsychotic agent, using human liver microsomes and expressed P450 isoforms. Quinidine (a specific inhibitor of CYP2D6) did not markedly affect the metabolism of perospirone, whereas quercetin (an inhibitor of CYP2C8) and ketoconazole (an inhibitor of CYP3A4) caused a decrease in the metabolism with human liver microsomes in a concentration dependent fashion. With 10 microM quercetin, the metabolism of perospirone was inhibited by 60.0% and with 1 microM ketoconazole almost complete inhibition was apparent. Anti-CYP2C8 and anti-CYP2D6 antisera did not exert marked effects, whereas anti-CYP3A4 antiserum caused almost complete inhibition. With expressed P450s, K(m) and V(max) values were 1.09 microM and 1.93 pmol/min/pmol P450 for CYP2C8, 1.38 microM and 5.73 pmol/min/pmol P450 for CYP2D6, and 0.245 microM and 61.3 pmol/min/pmol P450 for CYP3A4, respectively. These results indicated that the metabolism of perospirone in human liver was mainly catalysed by CYP3A4, and to a lesser extent CYP2C8 and CYP2D6 were responsible because kinetic data (K(m) and V(max)) of CYP2C8 and CYP2D6 suggested catalytic potential. 相似文献
89.
Yamada Y Hossain M Kimura Y Nakamura Y Masuda Y Shimizu Y Matsumoto K 《The Journal of clinical pediatric dentistry》2007,31(3):199-201
In the present study, removal of artifcial plaque in pits and fissures with the Carisolv system was compared with that of conventional bristle brush methoda in vitro. The results indicate that in the dental clinic, complete plaque removal with the Carisolv is possible, and in addition to acid etching, treated cavity was almost free of debris which might increase sealant retention. 相似文献
90.
A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced‐intensity conditioning 下载免费PDF全文
Masaya Okada Taizo Tasaka Kazuhiro Ikegame Nobuyuki Aotsuka Takeshi Kobayashi Yuho Najima Yoshiko Matsuhashi Hideho Wada Hirotoshi Tokunaga Shinichi Masuda Yoshikazu Utsu Satoshi Yoshihara Katsuji Kaida Takashi Daimon Hiroyasu Ogawa 《European journal of haematology》2018,100(4):335-343
Cord blood transplantation (CBT) is associated with delayed hematopoietic recovery and graft failure. To overcome these problems, we conducted a prospective, multicenter phase II study of intrabone marrow transplantation in which patients received reduced‐intensity conditioning without anti‐thymocyte globulin (ATG). The primary endpoint was the probability of full donor engraftment. Forty patients with hematologic malignancies were enrolled. Cord blood (CB) cells were injected without washing into 4 iliac bone sites (2 at each hemipelvis), at which approximately 6 mL of CB was administered at one site with local anesthesia. Full donor engraftment rate was 86.8%. The cumulative incidence of neutrophil and platelet engraftment was 86.4% and 85.5%, respectively. The median time to neutrophil (>0.5 × 109/L) and platelet (2.0 × 109/L) recovery was 17.5 and 44 days, respectively. The probability of severe acute graft‐vs‐host disease (GVHD) was 47.5%. The cumulative incidence of extensive chronic GVHD was 3.0%. The probability of relapse and non‐relapse mortality was 30.4% and 28.0%, respectively. The survival rate at 3 years was 45.6%, although most patients were at an advanced stage. These results suggest that our intrabone marrow‐CBT procedure without using ATG improves hematopoietic recovery and decreases the incidence of chronic GVHD, but does not decrease the incidence of acute GVHD. 相似文献